Código QR (código de barras bidimensional)

A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale

Background: The response of atopic dermatitis (AD) to different biologics and JAK inhibitors (JAKibs) is variable due to the varied immunological endotypes of AD. Aim and Objectives: To assess the effectiveness and adverse effect profile of tofacitinib in recalcitrant, moderate-to-severe AD patients...

ver descrição completa

Na minha lista:
Principais autores: Kabir Sardana, Savitha Sharath, Sumitra Kumari Meena, Ananta Khurana, Bhawuk Dhir
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Medknow Publications 2025-05-01
coleção:Indian Dermatology Online Journal
Assuntos:
atopic dermatitis
cyclosporine
dupilumab
easi
efficacy
jak inhibitors
th1
th2
th17
th22
tofacitinib
Acesso em linha:https://journals.lww.com/10.4103/idoj.idoj_665_24
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados